HFCAS OpenIR
Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells
Qu, Bingxue1,2; Xu, Yongjin1; Lu, Yang2; Zhuang, Weihao2; Jin, Xinxin2; Shi, Qiuqiu2; Yan, Shike2; Guo, Yu2; Shen, Zheyuan3; Che, Jinxin2,3; Wu, Yize2; Tong, Lexian3; Dong, Xiaowu2,3,4; Yang, Haiyan1
2022-05-05
发表期刊EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
ISSN0223-5234
通讯作者Dong, Xiaowu(dongxw@zju.edu.cn) ; Yang, Haiyan(yanghy@zjcc.org.cn)
摘要Multiple myeloma (MM) is a highly malignant hematologic cancer that occurs when an atypical plasma cell develops in the bone marrow and reproduces quickly. Despite varies of new drugs have been developed or under clinic trial, MM is still essentially incurable, while XPO1 inhibition has emerged as a promising therapeutic strategy in the treatment of MM. Using the second-generation XPO1 inhibitor KPT-8602 as the lead compound, structure-based optimization provided D4 with high anti-proliferation efficacy (IC50 =& nbsp;24 nM in MM.1S). In addition, the treatment with D4 significantly induced MM.1S cell cycle arrested and cell apoptosis, which was confirmed as on-target effect by immunofluorescence microscopy and competitive binding assay. Moreover, D4 displayed good metabolic stability over rat plasma and liver microsomes, as well as good pharmacokinetic profile on SD rat model with high drug exposure and decent bioavailability by oral gavage. All these good properties of D4 pave the way for further drug development and clinical application. (C)& nbsp;2022 Elsevier Masson SAS. All rights reserved.
关键词XPO1 Multiple myeloma MM.1S N-phenylsulfonamide Oral administration
DOI10.1016/j.ejmech.2022.114257
关键词[WOS]NUCLEAR EXPORT SINE ; SELECTIVE INHIBITORS ; THERAPEUTIC TARGET ; DRUG-METABOLISM ; TRANSPORT
收录类别SCI
语种英语
资助项目National Natural Science Foundation of China[82173660] ; National Natural Science Foundation of China[82103975] ; Natural Science Foundation of Zhejiang Province[LR21H300003] ; Natural Science Foundation of Zhejiang Province[LQ21H300005] ; Natural Science Foundation of Zhejiang Province[Q22H302109]
项目资助者National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province
WOS研究方向Pharmacology & Pharmacy
WOS类目Chemistry, Medicinal
WOS记录号WOS:000793692700002
出版者ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.hfcas.ac.cn:8080/handle/334002/130952
专题中国科学院合肥物质科学研究院
通讯作者Dong, Xiaowu; Yang, Haiyan
作者单位1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Univ Chinese Acad Sci, Zhejiang Canc Hosp,Canc Hosp,Dept Lymphoma, Hangzhou, Peoples R China
2.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Hangzhou, Peoples R China
3.Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou, Peoples R China
4.Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714
Qu, Bingxue,Xu, Yongjin,Lu, Yang,et al. Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2022,235.
APA Qu, Bingxue.,Xu, Yongjin.,Lu, Yang.,Zhuang, Weihao.,Jin, Xinxin.,...&Yang, Haiyan.(2022).Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,235.
MLA Qu, Bingxue,et al."Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 235(2022).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qu, Bingxue]的文章
[Xu, Yongjin]的文章
[Lu, Yang]的文章
百度学术
百度学术中相似的文章
[Qu, Bingxue]的文章
[Xu, Yongjin]的文章
[Lu, Yang]的文章
必应学术
必应学术中相似的文章
[Qu, Bingxue]的文章
[Xu, Yongjin]的文章
[Lu, Yang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。